| Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Doses of GC021109 in Healthy Subjects (NCT02254369) | GliaCure, Inc. | 2014-09-01 |
| Drug-drug Interaction Between Digoxin, Furosemide, Metformin, and Rosuvastatin (NCT02231931) | Boehringer Ingelheim | 2014-09-01 |
| Drug-Drug Interaction Study to Evaluate the Pharmacokinetics and Safety of CTX 4430 and Midazolam (NCT02233244) | Celtaxsys, Inc. | 2014-09-01 |
| LINEAR II - LME-159 Evaluation of a Multi-Electrode Linear Type Ablation Catheter (NCT02257060) | Biosense Webster, Inc. | 2014-09-01 |
| A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP) (NCT02229422) | University of California, San Diego | 2014-09-01 |
| Curriculum Evaluation of a Novel Health and Wellness Program Within New York City Schools (NCT02329015) | Long Island University | 2014-09-01 |
| A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects (REFLECTIONS B538-07)) (NCT02237729) | Pfizer | 2014-09-01 |
| Assessment of the Analgesic Effects of PF-06372865 in Healthy Volunteers Using Evoked Pain Endpoints (NCT02238717) | Pfizer | 2014-09-01 |
| Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric Cancer (NCT02378389) | Jiangsu HengRui Medicine Co., Ltd. | 2014-09-01 |
| TAK-385 Phase I Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability Study (NCT02252354) | Takeda | 2014-09-01 |
| VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors (NCT02164838) | Children's Oncology Group | 2014-09-01 |
| A Safety Study of sNN0029 Administration Via Intracerebroventricular Route to Patients With ALS (NCT01999803) | Newron Sweden AB | 2014-09-01 |
| A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline (NCT02080078) | AHS Cancer Control Alberta | 2014-09-01 |
| Allogeneic Islet Cells Transplanted Onto the Omentum (NCT02213003) | Rodolfo Alejandro | 2014-09-01 |
| Role Of Phosphorus And FGF 23 In Patients With Dent Disease (NCT02016235) | Mayo Clinic | 2014-09-01 |
| A Study to Compare the Bioavailability Intranasal Administration of 200 and 400 µg or 400 µg Alone of OPTINOSE™ FLUTICASONE With 440 µg of Flovent® HFA (Fluticasone Propionate) Inhalation Aerosol (Part 2) (NCT02266927) | Optinose US Inc. | 2014-09-01 |
| A Clinical Study to Evaluate Z7200 (Budesonide/Formoterol) Pharmacokinetics Profile in Healthy Volunteers (NCT02237508) | Zambon SpA | 2014-09-01 |
| Clinical Test of the MRgHIFU System on Uterine Fibroids (NCT02283502) | Chin-Jung Wang | 2014-09-01 |
| A Safety Study of Sativex Compared With Placebo (Both With Dose-intense Temozolomide) in Recurrent Glioblastoma Patients (NCT01812616) | Jazz Pharmaceuticals | 2014-09-01 |
| Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Advanced Non Small Cell Lung Cancer (NCT02274337) | Sun Yat-sen University | 2014-09-01 |
| Cytochrome P450 2D6 Genotype on the Clinical Effect of Carvedilol (NCT02286934) | Seoul National University Hospital | 2014-09-01 |
| Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults (NCT02238756) | CureVac | 2014-09-01 |
| A Study of TAS-205 for Duchenne Muscular Dystrophy (NCT02246478) | Taiho Pharmaceutical Co., Ltd. | 2014-09-01 |
| A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis (NCT02193815) | Pfizer | 2014-09-01 |
| Safety and Efficacy of BMMNCin Patients With Mental Retardation (NCT01908400) | Chaitanya Hospital, Pune | 2014-09-01 |
| Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Patients Infected With Burkholderia Cepacia Complex (NCT02212587) | Unity Health Toronto | 2014-09-01 |
| Study the Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Optic Nerve Disease (NCT01834079) | Chaitanya Hospital, Pune | 2014-09-01 |
| Saving Life and Limb: FES for the Elderly With PAD (NCT02384980) | MultiCare Health System Research Institute | 2014-09-01 |
| Safety Study of Immune System Modulator for Autoimmune Diseases (NCT02243683) | Artax Biopharma Inc | 2014-09-01 |
| Food Effect on Pharmacokinetic Parameters of ABX464 (NCT02731885) | Abivax S.A. | 2014-09-01 |
| A Clinical Trial to Study the Safety and Efficacy of Bone Marrow Derived Autologous Cell for the Treatment of Stroke. (NCT01832428) | Chaitanya Hospital, Pune | 2014-09-01 |
| First in Human Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of BAY1214784 (NCT02212080) | Bayer | 2014-09-01 |
| Prostate Cancer Genomic Heterogeneity (NCT02022371) | University College London Hospitals | 2014-09-01 |
| A Phase 1 Study Assessing Local Cutaneous Effects of SB204 (NCT02250430) | Novan, Inc. | 2014-09-01 |
| Bioequivalence Study Coadministered to Healthy Subjects in the Fasted State (NCT02223065) | AstraZeneca | 2014-09-01 |
| Open Label Study of DS-5573a (NCT02192567) | Daiichi Sankyo Co., Ltd. | 2014-09-01 |
| A Study to Compare the Adhesiveness of 2 Different Rotigotine Patches Used for the Treatment of Parkinson's Disease (NCT02230904) | UCB BIOSCIENCES GmbH | 2014-09-01 |
| A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus (NCT02239354) | ViaCyte | 2014-09-01 |
| Safety and Immunogenicity Study of a DNA Vaccine Combined With Protein Vaccine Against HIV/AIDS (NCT02376582) | EuroVacc Foundation | 2014-09-01 |
| Effectiveness and Safety of Method of Maxilla Alveolar Process Reconstruction Using Synthetic Tricalcium Phosphate and Autologous MMSCs (NCT02209311) | Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation | 2014-09-01 |
| CKD-397 Drug-drug Interaction Study (A) (NCT02247518) | Chong Kun Dang Pharmaceutical | 2014-09-01 |
| Clinical Study to Evaluate Safety and Efficacy of BMMNC in Retinitis Pigmentosa (NCT01914913) | Chaitanya Hospital, Pune | 2014-09-01 |
| Microtracer Study to Establish Absolute Bioavailability and the Absorption, Metabolism, Excretion of DA-1229 (NCT02267902) | Dong-A ST Co., Ltd. | 2014-09-01 |
| Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer (NCT02386397) | Institut du Cancer de Montpellier - Val d'Aurelle | 2014-09-01 |
| Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma (NCT02260492) | Oriel Therapeutics | 2014-09-01 |
| A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of ALS-008176 (NCT02231671) | Alios Biopharma Inc. | 2014-08-31 |
| Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Positron Emission Tomography (PET) Imaging of Tau in Healthy and Alzheimer's Disease (AD) Participants (NCT02187627) | Hoffmann-La Roche | 2014-08-31 |
| Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer (NCT02188264) | National Cancer Institute (NCI) | 2014-08-29 |
| A Study to Evaluate Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban (NCT02213029) | GlaxoSmithKline | 2014-08-28 |
| A Pharmacokinetic Study of Eltrombopag 50 Milligram (mg) in Healthy Volunteers Under Fasting Conditions (NCT02254434) | GlaxoSmithKline | 2014-08-28 |
| Safety, Tolerability, and Immunogenicity of the Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO), VRC-EBOADC069-00-VP, in Healthy Adults (NCT02231866) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-08-27 |
| A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML) (NCT02177812) | GlaxoSmithKline | 2014-08-27 |
| MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy (NCT02089230) | M.D. Anderson Cancer Center | 2014-08-27 |
| A Study of a Single Dose of ALXN1210 in Healthy Participants (NCT05288660) | Alexion Pharmaceuticals, Inc. | 2014-08-27 |
| Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors (NCT02239900) | M.D. Anderson Cancer Center | 2014-08-26 |
| Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation (NCT02226861) | National Heart, Lung, and Blood Institute (NHLBI) | 2014-08-26 |
| A Study to Evaluate Pharmacokinetic Parameters and Safety of Eliglustat Absorption Through the Mouth (NCT06193304) | Sanofi | 2014-08-25 |
| A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies (NCT02223598) | Cleave Biosciences, Inc. | 2014-08-25 |
| Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell Disease (NCT02225132) | National Heart, Lung, and Blood Institute (NHLBI) | 2014-08-23 |
| Diffuse Optical Imaging With Indocyanine Green Solution in Imaging Pelvic Lymph Nodes in Patients With Stage II Prostate Cancer Undergoing Surgery (NCT02119858) | City of Hope Medical Center | 2014-08-22 |
| Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery (NCT02120222) | Kari Kendra | 2014-08-22 |
| Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function (NCT02214147) | Millennium Pharmaceuticals, Inc. | 2014-08-21 |
| Study of Cytoreductive Surgery and Hyperthermic Intrathoracic Pleural Chemotherapy (HITC) With Escalating Doses for Children and Adolescents With Unilateral Pleural Malignancy (NCT01998529) | M.D. Anderson Cancer Center | 2014-08-20 |
| A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0123-0338 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus (NCT02220296) | Novo Nordisk A/S | 2014-08-20 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery (NCT02194829) | National Cancer Institute (NCI) | 2014-08-19 |
| Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer (NCT01790035) | Washington University School of Medicine | 2014-08-19 |
| Safety, Tolerability and Pharmacokinetics of DCBCI0901 in Patients With Advanced Solid Tumor (NCT02151357) | Standard Chem. & Pharm. Co., Ltd. | 2014-08-19 |
| Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab (NCT02275156) | Amgen | 2014-08-19 |
| A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors (NCT02174172) | Hoffmann-La Roche | 2014-08-18 |
| Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia (NCT02157324) | Acerta Pharma BV | 2014-08-18 |
| A Study in Healthy Volunteers to Compare the Profiles of DA-3880 and EU Sourced ARANESP® (Amgen) (NCT02241200) | Dong-A ST Co., Ltd. | 2014-08-18 |
| Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas (NCT02228512) | National Cancer Institute (NCI) | 2014-08-15 |
| A Single Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects (NCT04467060) | Sihuan Pharmaceutical Holdings Group Ltd. | 2014-08-14 |
| Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma (NCT02203526) | National Cancer Institute (NCI) | 2014-08-14 |
| Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma (NCT02270034) | Grupo Español de Investigación en Neurooncología | 2014-08-13 |
| Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma (NCT02159755) | National Cancer Institute (NCI) | 2014-08-13 |
| A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies (NCT02205333) | MedImmune LLC | 2014-08-13 |
| Study of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients (NCT02177682) | Novartis Pharmaceuticals | 2014-08-13 |
| Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma (NCT02163057) | Inovio Pharmaceuticals | 2014-08-13 |
| A Study to Assess Safety and Pharmacokinetics of MOXR0916 in Participants With Locally Advanced or Metastatic Solid Tumors (NCT02219724) | Genentech, Inc. | 2014-08-12 |
| Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers (NCT02167594) | Avid Radiopharmaceuticals | 2014-08-12 |
| Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma (NCT02215967) | National Cancer Institute (NCI) | 2014-08-12 |
| Copanlisib Pharmacodynamic Study (NCT02155582) | Bayer | 2014-08-12 |
| A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients (NCT02096601) | NeuroDerm Ltd. | 2014-08-11 |
| Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (NCT01898793) | Washington University School of Medicine | 2014-08-11 |
| A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes (NCT02212067) | Novo Nordisk A/S | 2014-08-11 |
| UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia (NCT02222688) | Thomas Kipps | 2014-08-08 |
| Study of the Absorption, Metabolism, and Route of Elimination of a Novel Class of Anti-HIV 1 Drugs (BMS-955176) in Humans. (NCT02206711) | ViiV Healthcare | 2014-08-08 |
| Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function (NCT02210871) | Novo Nordisk A/S | 2014-08-07 |
| Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies (NCT02189174) | Novartis Pharmaceuticals | 2014-08-07 |
| Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma (NCT02112526) | Acerta Pharma BV | 2014-08-07 |
| A Study of Eltrombopag in Patients With CMML and Thrombocytopenia (NCT02323178) | Groupe Francophone des Myelodysplasies | 2014-08-07 |
| Evaluation of the Tolerance of Afatinib in Combination With Docetaxel and Cisplatin in LAHNSCC Induction Chemotherapy (NCT02216617) | Groupe Oncologie Radiotherapie Tete et Cou | 2014-08-06 |
| Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine (NCT02648425) | ASLAN Pharmaceuticals | 2014-08-05 |
| A Single Ascending Dose Study in Healthy Participants and Multiple Ascending Dose Study of CNTO 7160 in Participants With Asthma and Participants With Atopic Dermatitis (NCT02345928) | Janssen Research & Development, LLC | 2014-08-05 |
| AZD9291 in Combination With Ascending Doses of Novel Therapeutics (NCT02143466) | AstraZeneca | 2014-08-05 |
| Elpipodect (MK-8189) Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003) (NCT02181803) | Merck Sharp & Dohme LLC | 2014-08-05 |
| Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (NCT02024087) | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | 2014-08-04 |
| Bioavailability Study of Enoxaparin Sodium Chemi and Clexane s.c. (NCT02232802) | Chemi S.p.A. | 2014-08-04 |
| α-TEA in Advanced Cancer (NCT02192346) | Providence Health & Services | 2014-08-04 |